001367 海森药业
已收盘 12-05 15:00:00
资讯
新帖
简况
海森药业(001367)披露董事、高级管理人员减持股份预披露公告,12月5日股价下跌0.31%
证券之星 · 12-05 17:50
海森药业(001367)披露董事、高级管理人员减持股份预披露公告,12月5日股价下跌0.31%
12月4日增减持汇总:飞沃科技等2股增持 海森药业等9股减持(表)
新浪证券 · 12-04 21:55
12月4日增减持汇总:飞沃科技等2股增持 海森药业等9股减持(表)
海森药业(001367)披露完成工商变更登记并换发营业执照,12月4日股价下跌1.97%
证券之星 · 12-04
海森药业(001367)披露完成工商变更登记并换发营业执照,12月4日股价下跌1.97%
海森药业:浙商资管、光大保德信基金等多家机构于12月3日调研我司
证券之星 · 12-04
海森药业:浙商资管、光大保德信基金等多家机构于12月3日调研我司
海森药业:截至2025年11月30日股东户数约1.1万户
证券之星 · 12-03
海森药业:截至2025年11月30日股东户数约1.1万户
海森药业(001367)披露部分募投项目结项并将节余募集资金投入新项目,11月28日股价下跌0.43%
证券之星 · 11-28
海森药业(001367)披露部分募投项目结项并将节余募集资金投入新项目,11月28日股价下跌0.43%
海森药业(001367)披露部分募投项目结项并将节余募集资金投入新项目公告,10月30日股价下跌0.26%
证券之星 · 10-30
海森药业(001367)披露部分募投项目结项并将节余募集资金投入新项目公告,10月30日股价下跌0.26%
海森药业(001367)披露2024年限制性股票激励计划预留授予登记完成公告,10月27日股价上涨0.38%
证券之星 · 10-27
海森药业(001367)披露2024年限制性股票激励计划预留授予登记完成公告,10月27日股价上涨0.38%
海森药业(001367)2025年三季报简析:营收净利润同比双双增长
证券之星 · 10-23
海森药业(001367)2025年三季报简析:营收净利润同比双双增长
海森药业(001367)9月30日股东户数1.15万户,较上期减少9.06%
证券之星 · 10-21
海森药业(001367)9月30日股东户数1.15万户,较上期减少9.06%
海森药业(001367.SZ)发布前三季度业绩,归母净利润8820.96万元,增长1.45%
智通财经 · 10-21
海森药业(001367.SZ)发布前三季度业绩,归母净利润8820.96万元,增长1.45%
海森药业(001367)披露2024年限制性股票激励计划预留授予名单核查结果,9月22日股价下跌1.08%
证券之星 · 09-22
海森药业(001367)披露2024年限制性股票激励计划预留授予名单核查结果,9月22日股价下跌1.08%
海森药业董事代亚辞任非独立董事职务 转任职工代表董事
中金财经 · 09-12
海森药业董事代亚辞任非独立董事职务 转任职工代表董事
海森药业收盘上涨1.61%,滚动市盈率32.19倍,总市值40.34亿元
金融界 · 08-25
海森药业收盘上涨1.61%,滚动市盈率32.19倍,总市值40.34亿元
海森药业(001367)2025年中报简析:营收净利润同比双双增长
证券之星 · 08-16
海森药业(001367)2025年中报简析:营收净利润同比双双增长
海森药业吴洋宽升任副总经理,24年薪酬仅为13万,近一年股价上涨63.87%
新浪证券 · 08-15
海森药业吴洋宽升任副总经理,24年薪酬仅为13万,近一年股价上涨63.87%
海森药业最新公告:上半年净利润同比增长4.74%
证券之星 · 08-14
海森药业最新公告:上半年净利润同比增长4.74%
7月31日海森药业(001367)龙虎榜数据:游资章盟主上榜
证券之星 · 07-31
7月31日海森药业(001367)龙虎榜数据:游资章盟主上榜
海森药业:在研产品共计17项涉及多个领域
证券之星 · 07-14
海森药业:在研产品共计17项涉及多个领域
浙江海森药业董事艾林完成减持147万股 套现约3200万元
中访网财观 · 07-03
浙江海森药业董事艾林完成减持147万股 套现约3200万元
加载更多
公司概况
公司名称:
浙江海森药业股份有限公司
所属行业:
医药制造业
上市日期:
2023-04-10
主营业务:
浙江海森药业股份有限公司的主营业务是化学药品原料药及中间体研发、生产和销售。公司的主要产品是化学药品原料药、中间体。公司先后获得了浙江省“专精特新”中小企业,创新型中小企业,科技型中小企业,AAA级“守合同重信用”企业,第二批制造业“云上企业”;金华市优秀企业金星奖,专利示范企业;东阳市“工业强市贡献奖”,“纳税百强”,政府质量奖等荣誉称号。
发行价格:
44.48
{"stockData":{"symbol":"001367","market":"SZ","secType":"STK","nameCN":"海森药业","latestPrice":22.79,"timestamp":1764918219000,"preClose":22.86,"halted":0,"volume":1062824,"delay":0,"changeRate":-0.0031,"floatShares":39697700,"shares":152000000,"eps":0.8128,"marketStatus":"已收盘","change":-0.07,"latestTime":"12-05 15:00:00","open":22.85,"high":23,"low":22.33,"amount":24026600,"amplitude":0.0293,"askPrice":22.8,"askSize":100,"bidPrice":22.79,"bidSize":95,"shortable":0,"etf":0,"ttmEps":0.8128,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":22.86,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":25.15,"lowLimit":20.57,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":152351200,"isCdr":false,"pbRate":2.43,"roa":"--","peRate":28.038878,"roe":"6.35%","epsLYR":1.22,"committee":0.115265,"marketValue":3472000000,"turnoverRate":0.0268,"status":1,"floatMarketCap":905000000},"requestUrl":"/m/hq/s/001367","defaultTab":"news","newsList":[{"id":"2589895339","title":"海森药业(001367)披露董事、高级管理人员减持股份预披露公告,12月5日股价下跌0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589895339","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589895339?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:50","pubTimestamp":1764928235,"startTime":"0","endTime":"0","summary":"截至2025年12月5日收盘,海森药业报收于22.79元,较前一交易日下跌0.31%,最新总市值为34.72亿元。该股当日开盘22.85元,最高23.0元,最低22.33元,成交额达2402.66万元,换手率为2.68%。近日,海森药业发布关于公司董事、高级管理人员减持股份的预披露公告。减持原因为个人资金需要,股份来源为公司2024年限制性股票激励计划首次授予部分第一个解除限售期解除限售的股份。上述人员减持数量均未超过其持有股份总数的25%,减持价格将按市场价格确定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500027966.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["001367","BK0239"],"gpt_icon":0},{"id":"2588887911","title":"12月4日增减持汇总:飞沃科技等2股增持 海森药业等9股减持(表)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588887911","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588887911?lang=zh_cn&edition=full","pubTime":"2025-12-04 21:55","pubTimestamp":1764856500,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! 据统计,12月4日,盘后飞沃科技、东阿阿胶披露增持情况。包括海森药业、海科新源、ST瑞和、联动科技、深科技、德艺文创、太阳电缆、中自科技、东望时代在内的9家A股上市公司披露减持情况。\n\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-04/doc-infzrzsu0235429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301232","001367","BK0259","BK0239"],"gpt_icon":0},{"id":"2588008850","title":"海森药业(001367)披露完成工商变更登记并换发营业执照,12月4日股价下跌1.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588008850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588008850?lang=zh_cn&edition=full","pubTime":"2025-12-04 17:31","pubTimestamp":1764840676,"startTime":"0","endTime":"0","summary":"截至2025年12月4日收盘,海森药业报收于22.86元,较前一交易日下跌1.97%,最新总市值为34.83亿元。公司近日发布公告称,浙江海森药业股份有限公司已于近期完成工商变更登记及《公司章程》备案手续,并取得浙江省市场监督管理局换发的营业执照。此次变更涉及注册资本调整,由“壹亿伍仟壹佰玖拾贰万陆仟肆佰肆拾元”变更为“壹亿伍仟贰佰叁拾伍万壹仟贰佰元整”。除注册资本外,营业执照其他内容未发生变化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400027311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","001367"],"gpt_icon":0},{"id":"2588504076","title":"海森药业:浙商资管、光大保德信基金等多家机构于12月3日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2588504076","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588504076?lang=zh_cn&edition=full","pubTime":"2025-12-04 09:16","pubTimestamp":1764811003,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年12月3日海森药业发布公告称浙商资管、光大保德信基金、中信证券于2025年12月3日调研我司。公司密切跟踪市场动态,积极协调产销衔接,以保障对客户订单的及时、充足交付。目前,公司生产经营活动按计划正常、有序开展。全年最终业绩完成情况,请以公司届时披露的定期报告为准。海森药业主营业务:从事化学药品原料药及中间体研发、生产和销售的高新技术企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400005538.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","001367"],"gpt_icon":0},{"id":"2588909880","title":"海森药业:截至2025年11月30日股东户数约1.1万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588909880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588909880?lang=zh_cn&edition=full","pubTime":"2025-12-03 08:54","pubTimestamp":1764723255,"startTime":"0","endTime":"0","summary":"证券之星消息,海森药业(001367)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止到2025年11月30日,公司股东人数是多少?海森药业回复:尊敬的投资者,您好!截至2025年11月30日,公司股东总户数约为1.1万户。谢谢您的关注和支持!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300004441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["001367","BK0239"],"gpt_icon":0},{"id":"2586733209","title":"海森药业(001367)披露部分募投项目结项并将节余募集资金投入新项目,11月28日股价下跌0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586733209","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586733209?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:40","pubTimestamp":1764340807,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘,海森药业报收于23.02元,较前一交易日下跌0.43%,最新总市值为35.07亿元。近日,浙江海森药业股份有限公司召开2025年第三次临时股东会,审议通过《关于部分募投项目结项并将节余募集资金投入新项目的议案》及《关于变更注册资本、修订<公司章程>并办理工商变更登记的议案》。出席会议股东及代理人共188人,代表有表决权股份总数的74.3464%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800040985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","001367"],"gpt_icon":0},{"id":"2579537119","title":"海森药业(001367)披露部分募投项目结项并将节余募集资金投入新项目公告,10月30日股价下跌0.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579537119","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579537119?lang=zh_cn&edition=full","pubTime":"2025-10-30 18:10","pubTimestamp":1761819050,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘,海森药业报收于23.28元,较前一交易日下跌0.26%,最新总市值为35.47亿元。该股当日开盘23.36元,最高23.6元,最低23.21元,成交额达2433.78万元,换手率为2.62%。近日,海森药业发布公告称,公司将于2025年11月28日14:00召开2025年第三次临时股东会,会议将审议《关于部分募投项目结项并将节余募集资金投入新项目的议案》。该项议案涉及中小投资者利益,公司将对中小投资者的表决情况单独统计并披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000036115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","001367"],"gpt_icon":0},{"id":"2578214611","title":"海森药业(001367)披露2024年限制性股票激励计划预留授予登记完成公告,10月27日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578214611","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578214611?lang=zh_cn&edition=full","pubTime":"2025-10-27 17:54","pubTimestamp":1761558865,"startTime":"0","endTime":"0","summary":"截至2025年10月27日收盘,海森药业报收于24.09元,较前一交易日上涨0.38%,最新总市值为36.6亿元。该股当日开盘23.98元,最高24.23元,最低23.91元,成交额达2772.95万元,换手率为2.98%。公告显示,公司已完成2024年限制性股票激励计划的预留授予登记,授予日为2025年9月11日,上市日为2025年10月30日。本次授予后公司总股本增至152,351,200股,控股股东持股比例由68.51%被动稀释至68.32%,未导致控制权变更。2025年、2026年业绩考核目标以2023年营收或净利润为基数设定增长指标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700026778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["001367","BK0239"],"gpt_icon":0},{"id":"2577317093","title":"海森药业(001367)2025年三季报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2577317093","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577317093?lang=zh_cn&edition=full","pubTime":"2025-10-23 06:03","pubTimestamp":1761170609,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期海森药业发布2025年三季报。根据财报显示,海森药业营收净利润同比双双增长。截至本报告期末,公司营业总收入3.59亿元,同比上升12.13%,归母净利润8820.96万元,同比上升1.45%。按单季度数据看,第三季度营业总收入1.17亿元,同比上升6.74%,第三季度归母净利润2741.55万元,同比下降5.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300004064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["001367"],"gpt_icon":0},{"id":"2577828347","title":"海森药业(001367)9月30日股东户数1.15万户,较上期减少9.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577828347","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577828347?lang=zh_cn&edition=full","pubTime":"2025-10-21 17:12","pubTimestamp":1761037936,"startTime":"0","endTime":"0","summary":"证券之星消息,近日海森药业披露,截至2025年9月30日公司股东户数为1.15万户,较6月30日减少1146.0户,减幅为9.06%。在化学制药行业个股中,海森药业股东户数低于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.23万户。从股价来看,2025年6月30日至2025年9月30日,海森药业区间涨幅为7.57%,在此期间股东户数减少1146.0户,减幅为9.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100026044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["001367","BK0239"],"gpt_icon":0},{"id":"2577863840","title":"海森药业(001367.SZ)发布前三季度业绩,归母净利润8820.96万元,增长1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577863840","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577863840?lang=zh_cn&edition=full","pubTime":"2025-10-21 16:54","pubTimestamp":1761036846,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海森药业(001367.SZ)发布2025年三季度报告,该公司前三季度营业收入为3.59亿元,同比增长12.13%。归属于上市公司股东的净利润为8820.96万元,同比增长1.45%。归属于上市公司股东的扣除非经常性损益的净利润为8475.8万元,同比减少1.56%。基本每股收益为0.59元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["001367"],"gpt_icon":0},{"id":"2569733143","title":"海森药业(001367)披露2024年限制性股票激励计划预留授予名单核查结果,9月22日股价下跌1.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569733143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569733143?lang=zh_cn&edition=full","pubTime":"2025-09-22 22:46","pubTimestamp":1758552402,"startTime":"0","endTime":"0","summary":"截至2025年9月22日收盘,海森药业报收于23.92元,较前一交易日下跌1.08%,最新总市值为36.34亿元。公司近日发布公告称,董事会薪酬与考核委员会就公司2024年限制性股票激励计划预留授予激励对象名单发表了核查意见,并披露了公示情况。公告显示,浙江海森药业股份有限公司于2025年9月11日召开第三届董事会第十六次会议,审议通过向2024年限制性股票激励计划激励对象授予预留限制性股票的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200034985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["001367","BK0239"],"gpt_icon":0},{"id":"2566948184","title":"海森药业董事代亚辞任非独立董事职务 转任职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2566948184","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566948184?lang=zh_cn&edition=full","pubTime":"2025-09-12 08:10","pubTimestamp":1757635803,"startTime":"0","endTime":"0","summary":"代亚先生辞职后仍在公司担任其他职务,其辞职不会导致公司董事会成员低于法定人数,不影响董事会正常运作。同日,公司召开2025年第一次职工代表大会,选举代亚先生为第三届董事会职工代表董事,任期至本届董事会届满。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20250912/31636482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","001367"],"gpt_icon":0},{"id":"2562119542","title":"海森药业收盘上涨1.61%,滚动市盈率32.19倍,总市值40.34亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2562119542","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562119542?lang=zh_cn&edition=full","pubTime":"2025-08-25 16:26","pubTimestamp":1756110413,"startTime":"0","endTime":"0","summary":"8月25日,海森药业今日收盘26.55元,上涨1.61%,滚动市盈率PE达到32.19倍,总市值40.34亿元。从行业市盈率排名来看,公司所处的化学制药行业市盈率平均65.87倍,行业中值38.88倍,海森药业排名第83位。股东方面,截至2025年6月30日,海森药业股东户数12654户,较上次增加2782户,户均持股市值35.28万元,户均持股数量2.76万股。浙江海森药业股份有限公司的主营业务是化学药品原料药及中间体研发、生产和销售。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/25162652666454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["001367","BK0239"],"gpt_icon":0},{"id":"2559949015","title":"海森药业(001367)2025年中报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2559949015","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559949015?lang=zh_cn&edition=full","pubTime":"2025-08-16 06:05","pubTimestamp":1755295512,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期海森药业发布2025年中报。根据财报显示,海森药业营收净利润同比双双增长。截至本报告期末,公司营业总收入2.42亿元,同比上升14.93%,归母净利润6079.42万元,同比上升4.74%。按单季度数据看,第二季度营业总收入1.24亿元,同比上升30.33%,第二季度归母净利润2958.2万元,同比上升19.98%。管理费用变动幅度为29.34%,原因:股权激励及职工薪酬增加。筹资活动产生的现金流量净额变动幅度为47.3%,原因:现金分红减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081600004336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["001367"],"gpt_icon":0},{"id":"2559459839","title":"海森药业吴洋宽升任副总经理,24年薪酬仅为13万,近一年股价上涨63.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559459839","media":"新浪证券","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559459839?lang=zh_cn&edition=full","pubTime":"2025-08-15 21:20","pubTimestamp":1755264000,"startTime":"0","endTime":"0","summary":" 8月15日,浙江海森药业股份有限公司宣布,公司总经理助理吴洋宽晋升为副总经理。但吴洋宽在2024年获得了公司的股权激励3.6万股,本次升任公告中显示持股显示已增加到了5.3万股,显然逐步获得公司认可。 此外,公司截至8月15日,总市值约为40.81亿元人民币,近一年股价上涨63.87%。 根据海森药业2024年年度报告,公司全年实现营业收入4.72亿元,同比增长18.63%;归属于上市公司股东的净利润1.23亿元,同比增长17.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-08-15/doc-infmapwu1260701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["001367","BK0239"],"gpt_icon":0},{"id":"2559596029","title":"海森药业最新公告:上半年净利润同比增长4.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2559596029","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2559596029?lang=zh_cn&edition=full","pubTime":"2025-08-14 18:49","pubTimestamp":1755168587,"startTime":"0","endTime":"0","summary":"海森药业(001367.SZ)发布2025年半年度报告,公司上半年实现营业收入2.42亿元,同比增长14.93%;实现净利润6079.42万元,同比增长4.74%。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081400036475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["001367"],"gpt_icon":0},{"id":"2555888501","title":"7月31日海森药业(001367)龙虎榜数据:游资章盟主上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2555888501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555888501?lang=zh_cn&edition=full","pubTime":"2025-07-31 17:13","pubTimestamp":1753953193,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2025年7月31日公布的交易公开信息显示,海森药业因日换手率达到20%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年7月31日收盘,海森药业报收于26.55元,上涨3.71%,换手率35.09%,成交量13.58万手,成交额3.57亿元。从龙虎榜公布的当日买卖数据来看,机构合计净卖出1332.99万元。章盟主等知名游资榜上有名。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073100027360.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["001367","BK0239"],"gpt_icon":0},{"id":"2551906392","title":"海森药业:在研产品共计17项涉及多个领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2551906392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551906392?lang=zh_cn&edition=full","pubTime":"2025-07-14 16:30","pubTimestamp":1752481844,"startTime":"0","endTime":"0","summary":"证券之星消息,海森药业07月14日在投资者关系平台上答复投资者关心的问题。有没有创新药产品?公司目前在研产品共计17项,包括原料药、中间体和制剂产品,涉及抗病毒、抗抑郁、降血脂、非甾体抗炎、抗风湿、抗消化性溃疡等。在研产品进展情况和投入情况详见公司披露的《2024年年度报告》“第三节 管理层讨论与分析”之“四、主营业务分析”之“4、研发投入”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071400022187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["001367","BK0239"],"gpt_icon":0},{"id":"2548081169","title":"浙江海森药业董事艾林完成减持147万股 套现约3200万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548081169","media":"中访网财观","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548081169?lang=zh_cn&edition=full","pubTime":"2025-07-03 00:21","pubTimestamp":1751473260,"startTime":"0","endTime":"0","summary":"根据披露,艾林于2025年6月24日至7月1日期间通过集中竞价交易方式减持公司股份147.21万股,占公司总股本的0.969%,减持均价为21.73元/股,合计套现金额约3199.5万元。此次减持后,艾林持股数量降至454.21万股,其中无限售条件股份已全部减持完毕,剩余股份均为限售股。资料显示,艾林作为公司高管,其减持行为受任职期间“每年转让不超过持股25%”的限制。浙江海森药业总股本为1.52亿股,截至公告日,艾林已履行全部减持计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2025-07-03/doc-infecccw7615718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["001367","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765108684018,"stockEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0177},{"period":"3month","weight":-0.0792},{"period":"6month","weight":0.0089},{"period":"1year","weight":0.205},{"period":"ytd","weight":0.2452}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江海森药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11000人(较上一季度减少4.41%)","perCapita":"3608股","listingDate":"2023-04-10","address":"浙江省金华市东阳市六石街道香潭村","registeredCapital":"15235万元","survey":" 浙江海森药业股份有限公司的主营业务是化学药品原料药及中间体研发、生产和销售。公司的主要产品是化学药品原料药、中间体。公司先后获得了浙江省“专精特新”中小企业,创新型中小企业,科技型中小企业,AAA级“守合同重信用”企业,第二批制造业“云上企业”;金华市优秀企业金星奖,专利示范企业;东阳市“工业强市贡献奖”,“纳税百强”,政府质量奖等荣誉称号。","listedPrice":44.48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海森药业(001367)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海森药业(001367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海森药业,001367,海森药业股票,海森药业股票老虎,海森药业股票老虎国际,海森药业行情,海森药业股票行情,海森药业股价,海森药业股市,海森药业股票价格,海森药业股票交易,海森药业股票购买,海森药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海森药业(001367)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海森药业(001367)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}